Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Integrin alpha L/CD11a Antibody, Novus Biologicals™

Goat Polyclonal Antibody
Supplier: Novus Biologicals NBP151967
Description
Integrin alpha L/CD11a Polyclonal specifically detects Integrin alpha L/CD11a in Human samples. It is validated for Western Blot, Immunohistochemistry, Immunohistochemistry-Paraffin, Peptide ELISA.Specifications
Integrin alpha L/CD11a | |
Polyclonal | |
Unconjugated | |
Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA with 0.02% Sodium Azide | |
CD11 antigen-like family member A, CD11a antigen, CD11Aantigen CD11A (p180), lymphocyte function-associated antigen 1, alphapolypeptide, integrin alpha-L, integrin gene promoter, integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen1; alpha polypeptide), Leukocyte adhesion glycoprotein LFA-1 alpha chain, Leukocyte function-associated molecule 1 alpha chain, LFA-1, LFA-1 alpha, LFA1A, LFA-1A, lymphocyte function-associated antigen 1 | |
Goat | |
Affinity Purified | |
RUO | |
Primary | |
This antibody is expected to recognize both reported isoforms (NP_002200.2; NP_001107852.1). | |
Store at -20C. Avoid freeze-thaw cycles. |
Western Blot, Immunohistochemistry, Immunohistochemistry (Paraffin), ELISA | |
0.5 mg/mL | |
Western Blot 0.5-2 ug/ml, Immunohistochemistry 4 - 6 ug/ml, Immunohistochemistry-Paraffin 4-6 ug/ml, Peptide ELISA 1:16000 | |
NP_002200.2 | |
ITGAL | |
Peptide with sequence C-YQVRIQPSIHDHN corresponding to internal region according to NP_002200.2, NP_001107852.1. | |
0.1 mg | |
Adaptive Immunity, Cellular Markers, Cytokine Research, Hematopoietic Stem Cell Markers, Immunology, Myeloid Cell Markers, Signal Transduction, Stem Cell Markers | |
3683 | |
Human | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction